Therapeutic anti-melanoma compounds

• US 6,861,408 B2
• Filed: 05/21/2001
• Issued: 03/01/2005
• Est. Priority Date: 05/31/2000
• Status: Expired due to Term

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Nicolette, Charles A.
• Primary Examiner(s): Nickol, G.
• Assistant Examiner(s): Yaen, C.
• Application Number:
  US09/862,260
• Publication Number:
  US 20020082217A1
• Time in Patent Office: 1,380 Days
• Field of Search: 530/300, 530/328, 514/1, 514/15
• US Class Current: 514/19.3
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/464 characterised by the antigen targeted or presented
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.

Claims

1. A composition comprising at least one immunogenic ligand, wherein said immunogenic ligand elicits an immune response against a gp100 ligand, and wherein said immunogenic ligand is selected from the group consisting of FLDQVAFVV (SEQ ID NO:

5), FLDQVAFSV (SEQ ID NO;

7), FLFLWFFEV (SEQ ID NO;

9), FLDQRVFVV (SEQ ID NO;

11), FLTMWPGGV (SEQ ID NO;

13), FLSWEGLVV (SEQ ID NO;

15), FLIWEGYVV (SEQ ID NO;

17), FLDSVFNLV (SEQ ID NO;

19), and FLLWEGLVV (SEQ. ID NO;

21).

2. The composition of claim 1, wherein said at least one immunogenic ligand is FLFLWFFEV (SEQ ID NO:

9) or FLDQRVFVV (SEQ ID NO;

11).

3. The composition of claim 1, wherein said at least one immunogenic ligand is FLDQRVFVV (SEQ ID NO:

11).

4. The composition of claim 1, further comprising the ligand consisting of FLDQVPFSV (SEQ ID NO:

3) or ITDQVPFSV (SEQ ID NO;

23).

5. The composition of any one of claims 1 and 2 to 4, further comprising a carrier.

6. The composition of claim 5 wherein the carrier is a pharmaceutically acceptable carrier.